Contatta
la direzione medica.
Per informazioni o approfondimenti, è possibile contattare la Direzione Medica di Roche Italia
CONTATTA
Evoluzione patologica
Il momento in cui, durante l’emopoiesi, il normale processo di sviluppo viene interrotto, determina il tipo di leucemia o linfoma. Il DLBCL può essere diviso in due sottotipi principali che originano in fasi distinte del processo di maturazione delle cellule B: a cellule B del centro germinativo (GCB) e non-GCB, di cui il sottotipo più comune è quello a cellule B attivate (ABC).
Il sottotipo GCB deriva probabilmente dalle cellule B del centro germinativo, mentre il sottotipo ABC sembra derivare da cellule B in stadi successivi di sviluppo (durante la differenziazione plasmacitica). La distinzione tra questi diversi sottotipi ha significato prognostico, dal momento che il sottotipo ABC presenta una prognosi peggiore rispetto a GCB.5,6
M-IT-00002080
Info utili
-
Bibliografia
- Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60:393-408..
- National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer. 1982;49(10):2112-2135
- A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood. 1997;89(11):3909-3918.
- Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
- Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol. 2005;23(26):6351-6357.
- Carbone A, Gloghini A, Kwong YL, Younes A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol. 2014;93(8):1263-1277.
- Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146-171.
- Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2014;11(1):12-23.
- Morton LM, Wang SS, Devesa SS, Hartge P, Wei-senburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276.
- Shenoy PJ, Malik N, Nooka A, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Can-cer. 2011;117(11):2530-2540.
- Freedman, AS, Aster JC. Epidemiology, clinical manifestastions, pathologic features, and diagnosis of diffuse large B cell lymphoma. UpToDate Web site: http://www. uptodate. com/contents/epidemiology-clinical-manifestations-pathologic-features-and-diagno-sis-of-diffuse-large-b-cell-lymphoma?sour-ce=related_link. Accessed July 20, 2015.
- Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodg-kin’s Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780-2795.
- Longo DL. Malignancies of lymphoid cells. Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison’s Principles of Internal Medicine, 17th ed. New York, NY: McGraw-Hill; 2008
- NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin’s Lymphomas. V2.2016. http:// www.nccn.org/pro-fessionals/physician_gls/ pdf/LNH.pdf. Accessed February 16, 2016.
- Sneed TB, Medeiros L, Rodriguez JM. Agressive and highly agressive lymphomas. In: Kantarjian HM, Wolff RA, Koller CA, ed. MD Anderson Manual of Medical Oncology. New York, NY: McGraw-Hill; 2006
- Zelenetz AD, Abramson JS, Advani RH, et al. Non-Hodgkin’s lymphomas. J Natl Compr Canc Netw. 2011;9(5):484-560.
- Gatter K, Pezzella F. Diffuse large B-cell lymphoma. Diag Histopath. 2010;16(2):69-81.
- Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5(4):251- 262.
- Iqbal J, Greiner TC, Patel K, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007;21(11):2332-2343.
- Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
- Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.